153 related articles for article (PubMed ID: 30101563)
1. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies.
Watson N; Wu K; Farr P; Reynolds NJ; Hampton PJ
Br J Dermatol; 2019 Jan; 180(1):195-196. PubMed ID: 30101563
[No Abstract] [Full Text] [Related]
2. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
Gkini MA; Bewley AP
Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
[No Abstract] [Full Text] [Related]
3. A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature.
Echeverría-García B; Nuño-González A; Dauden E; Vanaclocha F; Torrado R; Belinchón I; Pérez-Zafrilla B;
Actas Dermosifiliogr; 2017 Mar; 108(2):168-170. PubMed ID: 27765165
[No Abstract] [Full Text] [Related]
4. Use of ustekinumab in five psoriatic patients with hepatitis B virus infection.
Piaserico S; Conti A; Coati I; Galdo G; Bernabucci V; Zanca A; Drabeni M; Masutti F; Musumeci ML; Alberti A; Russo FP
G Ital Dermatol Venereol; 2019 Jun; 154(3):376-377. PubMed ID: 28712266
[No Abstract] [Full Text] [Related]
5. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
Lund T; Thomsen SF
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
[TBL] [Abstract][Full Text] [Related]
7. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.
Gkalpakiotis S; Arenberger P; Fridman M; Arenbergerova M
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28730674
[No Abstract] [Full Text] [Related]
9. Treatment of severe psoriasis with ustekinumab during pregnancy.
Andrulonis R; Ferris LK
J Drugs Dermatol; 2012 Oct; 11(10):1240. PubMed ID: 23134993
[TBL] [Abstract][Full Text] [Related]
10. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis.
Javadzadeh S; Gkini MA; Panos GD; Adewoyin T; Bewley A
Clin Exp Dermatol; 2020 Aug; 45(6):802-804. PubMed ID: 32212270
[No Abstract] [Full Text] [Related]
11. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
[No Abstract] [Full Text] [Related]
12. Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study.
Blaszczak AM; Dunaway S; Ali Alikhan M; Kelly S; Levin D; Kaffenberger J
Int J Dermatol; 2019 Nov; 58(11):e228-e229. PubMed ID: 31334835
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
J Dermatolog Treat; 2019 Feb; 30(1):40-44. PubMed ID: 29676599
[TBL] [Abstract][Full Text] [Related]
15. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient.
Mugheddu C; Atzori L; Lappi A; Murgia S; Rongioletti F
Dermatol Ther; 2019 May; 32(3):e12895. PubMed ID: 30958637
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
[TBL] [Abstract][Full Text] [Related]
18. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
[TBL] [Abstract][Full Text] [Related]
19. A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal.
Lovero R; Losurdo G; Mastromauro M; Castellaneta NM; Mongelli A; Gentile A; Di Leo A; Principi M
Curr Drug Saf; 2018; 13(3):221-223. PubMed ID: 30027852
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
